Cargando…
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
This study aimed to: (1) estimate the disease burden of herpes zoster (HZ) and (2) assess the potential public health impact of introducing adjuvanted recombinant zoster vaccine (RZV) compared with no vaccination in adults aged ≥50 years in Argentina, Brazil, Mexico, Chile, and Colombia using the ZO...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026900/ https://www.ncbi.nlm.nih.gov/pubmed/36821856 http://dx.doi.org/10.1080/21645515.2022.2164144 |
_version_ | 1784909611809112064 |
---|---|
author | Han, Ru Gomez, Jorge A. de Veras, Bruna Pinto, Thatiana Guzman-Holst, Adriana Nieto, Javier van Oorschot, Désirée A. M. |
author_facet | Han, Ru Gomez, Jorge A. de Veras, Bruna Pinto, Thatiana Guzman-Holst, Adriana Nieto, Javier van Oorschot, Désirée A. M. |
author_sort | Han, Ru |
collection | PubMed |
description | This study aimed to: (1) estimate the disease burden of herpes zoster (HZ) and (2) assess the potential public health impact of introducing adjuvanted recombinant zoster vaccine (RZV) compared with no vaccination in adults aged ≥50 years in Argentina, Brazil, Mexico, Chile, and Colombia using the ZOster ecoNomic Analysis (ZONA) static multicohort Markov model. The model followed individuals aged ≥50 years from administration of RZV over their remaining lifetime. Inputs were based, most often, on local data. First dose coverage was assumed to be 35%, with 75% second dose compliance. It was predicted that without RZV, there would be 23,558,675 HZ cases, 6,115,981 post-herpetic neuralgia (PHN) cases, and 7,058,779 non-PHN complications in the five countries, but introducing RZV under assumed coverage could avoid 4,583,787 (19%) HZ cases, 1,130,751 (18%) PHN cases, and 1,373,419 (19%) non-PHN complications. Also, 10427,504 (20%) doctor’s office visits and 1,630,201 (19%) days of hospitalization could be averted in the three countries (Argentina, Brazil, and Mexico) with available input data. The numbers needed to be vaccinated to avoid one case of HZ were 9–10 across countries, and to avoid one case of PHN, 35–40. One-way sensitivity analyses showed that the input parameters with the largest impact on the estimated number of HZ cases avoided were first dose coverage, initial HZ incidence, and vaccine efficacy waning. In conclusion, the introduction of RZV for older adults in Latin America could greatly reduce the public health burden of HZ and reduce the related doctor visits and hospitalization days. |
format | Online Article Text |
id | pubmed-10026900 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-100269002023-03-21 How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Han, Ru Gomez, Jorge A. de Veras, Bruna Pinto, Thatiana Guzman-Holst, Adriana Nieto, Javier van Oorschot, Désirée A. M. Hum Vaccin Immunother Zoster This study aimed to: (1) estimate the disease burden of herpes zoster (HZ) and (2) assess the potential public health impact of introducing adjuvanted recombinant zoster vaccine (RZV) compared with no vaccination in adults aged ≥50 years in Argentina, Brazil, Mexico, Chile, and Colombia using the ZOster ecoNomic Analysis (ZONA) static multicohort Markov model. The model followed individuals aged ≥50 years from administration of RZV over their remaining lifetime. Inputs were based, most often, on local data. First dose coverage was assumed to be 35%, with 75% second dose compliance. It was predicted that without RZV, there would be 23,558,675 HZ cases, 6,115,981 post-herpetic neuralgia (PHN) cases, and 7,058,779 non-PHN complications in the five countries, but introducing RZV under assumed coverage could avoid 4,583,787 (19%) HZ cases, 1,130,751 (18%) PHN cases, and 1,373,419 (19%) non-PHN complications. Also, 10427,504 (20%) doctor’s office visits and 1,630,201 (19%) days of hospitalization could be averted in the three countries (Argentina, Brazil, and Mexico) with available input data. The numbers needed to be vaccinated to avoid one case of HZ were 9–10 across countries, and to avoid one case of PHN, 35–40. One-way sensitivity analyses showed that the input parameters with the largest impact on the estimated number of HZ cases avoided were first dose coverage, initial HZ incidence, and vaccine efficacy waning. In conclusion, the introduction of RZV for older adults in Latin America could greatly reduce the public health burden of HZ and reduce the related doctor visits and hospitalization days. Taylor & Francis 2023-02-23 /pmc/articles/PMC10026900/ /pubmed/36821856 http://dx.doi.org/10.1080/21645515.2022.2164144 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
spellingShingle | Zoster Han, Ru Gomez, Jorge A. de Veras, Bruna Pinto, Thatiana Guzman-Holst, Adriana Nieto, Javier van Oorschot, Désirée A. M. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? |
title | How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? |
title_full | How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? |
title_fullStr | How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? |
title_full_unstemmed | How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? |
title_short | How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? |
title_sort | how large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five latin american countries be? |
topic | Zoster |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026900/ https://www.ncbi.nlm.nih.gov/pubmed/36821856 http://dx.doi.org/10.1080/21645515.2022.2164144 |
work_keys_str_mv | AT hanru howlargecouldthepublichealthimpactofintroducingrecombinantzostervaccinationforpeopleaged50yearsinfivelatinamericancountriesbe AT gomezjorgea howlargecouldthepublichealthimpactofintroducingrecombinantzostervaccinationforpeopleaged50yearsinfivelatinamericancountriesbe AT deverasbruna howlargecouldthepublichealthimpactofintroducingrecombinantzostervaccinationforpeopleaged50yearsinfivelatinamericancountriesbe AT pintothatiana howlargecouldthepublichealthimpactofintroducingrecombinantzostervaccinationforpeopleaged50yearsinfivelatinamericancountriesbe AT guzmanholstadriana howlargecouldthepublichealthimpactofintroducingrecombinantzostervaccinationforpeopleaged50yearsinfivelatinamericancountriesbe AT nietojavier howlargecouldthepublichealthimpactofintroducingrecombinantzostervaccinationforpeopleaged50yearsinfivelatinamericancountriesbe AT vanoorschotdesireeam howlargecouldthepublichealthimpactofintroducingrecombinantzostervaccinationforpeopleaged50yearsinfivelatinamericancountriesbe |